Health Care · Pharmaceutical Preparations

RCUS Arcus Biosciences, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 1724521104 filings
Russell 2000

RCUS at a glance

Arcus Biosciences, Inc. (RCUS, SEC CIK 1724521) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as August 24, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Arcus Biosciences, Inc. (RCUS) reported revenue of $33.0 million (down 35.3% from FY2024) and a net loss of $353.0 million. Diluted EPS was -$3.29.
  • As of September 30, 2026, 30 institutional investment managers tracked by SignalX reported holding Arcus Biosciences, Inc. (RCUS) shares worth $2.0 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Azoy Alexander on August 21, 2026 of 2,827 shares at $30.00 per share.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$33.0M
−35.3% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
30 funds
$2.0B · −1 vs prior quarter
Latest 8-K
Nov 4, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business model: Development and commercialization of investigational pharmaceutical products in immuno-oncology
  • No new products or segments introduced; increased emphasis on regulatory, pricing, and healthcare reform risks in U.S. markets
  • Strategic risk focus shifted toward navigating U.S. drug pricing reforms and increased government healthcare cost containment measures
  • Significant stock ownership concentration with Gilead owning 25.1% and management owning 39.5% collectively as of December 31, 2025
  • Implementation of exclusive Delaware Court of Chancery forum for stockholder disputes to limit litigation venue options

Risk Factors

  • Regulatory risk from Gilead collaboration amendment causing revenue catch-up of $143M in 2025, impacting timing and recognition of license income
  • Macroeconomic exposure to collaboration funding variability, e.g., Taiho option revenue dropped from $15M in 2024 to $7M in 2025
  • Operational risk of impairment on right-of-use office assets due to 2024 updated space plans, reflecting changing facility requirements
  • Market disruption risk from Gilead's voluntary return of etrumadenant license, affecting Arcus's revenue and pipeline strategy
  • Financial risk from non-cash interest expenses related to liabilities under BVF royalty sale, impacting net income volatility

Management Discussion & Analysis

  • No product sales revenue; all revenue from license, collaboration, and development services agreements
  • License and development services revenue recognized based on percentage completion of R&D obligations
  • R&D expenses include clinical, payroll, supplies, consulting, contract research; expect near-term R&D decrease due to winding down domvanalimab studies
  • Cash, cash equivalents, and marketable securities totaled $1.0 billion as of Dec 31, 2025, sufficient to fund operations until at least H2 2028
  • Management highlights risks and uncertainties; key focus on advancing casdatifan and inflammation programs with potential increased late-stage investment

AI summary of the RCUS 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • Newly triggered compliance risk: U.S. BIOSECURE Act enacted December 2025 could restrict sole zimberelimab manufacturer WuXi Biologics
  • Most material operational update: etrumadenant development paused in third-line metastatic colorectal cancer to prioritize late-stage programs
  • Regulatory risk: FDA disruptions from funding shortages, staffing limitations, and policy changes could delay reviews and approvals
  • Competitive risk: Phase 3 STAR-221 discontinued after December 2025 interim analysis showed no benefit versus standard of care
  • Financial risk: $694 million cash, equivalents, and marketable securities funds planned operations into 2029; additional capital may still be required

Management Discussion & Analysis

  • Revenue decline, exact quarterly dollar amounts obscured in filing table, down 65% YoY overall
  • Net loss $128M vs $135M YoY, operating loss $131M vs $142M
  • Best program: casdatifan plus cabozantinib, median PFS 14.5 months and cORR 44%
  • Worst program: domvanalimab, PACIFIC-8 Phase 3 discontinued in August 2026
  • Operating cash use $345M vs $362M, October equity offering gross proceeds approximately $288M, runway into 2029

AI summary of the RCUS 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 4, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Arcus reported financial results for the nine months ended September 30, 2026
  • Exhibit 99.1 contains the detailed results and management commentary

Item EX-99.1: Item EX-99.1

  • Casdatifan clinical momentum: PEAK-1 enrollment expected complete within two to three months, with PEAK-20 Phase 3 initiation targeted for Q4 2026
  • ARC-20 results showed median PFS 14.5 months in second-line disease and median OS 35 months in heavily pretreated patients
Filed Oct 23, 2026Full analysis →

Item 8.01: Other Events

  • $269.7 million net proceeds strengthen Arcus’s cash position for development and corporate activities
  • 16,428,572 shares issued at $17.50 public offering price, creating material equity dilution
Filed Oct 21, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Preliminary liquidity of approximately $694.0 million in cash, equivalents and marketable securities as of September 30, 2026
  • Balance supports ongoing clinical development and operations, but runway cannot be assessed without burn-rate and expense data

AI summaries of RCUS 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for RCUS

Don't miss the next RCUS filing

  • Alerts as it files. A push when RCUS files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut RCUS, by share count.
  • Ask anything. An AI agent that reads every RCUS filing and answers with sources.

RCUS alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Azoy AlexanderMAug 21, 2026-
Azoy AlexanderSellAug 21, 2026$30.00
Azoy AlexanderMAug 21, 2026$15.44
Jaen Juan C.SellJul 10, 2026$28.61
Jaen Juan C.SellJul 10, 2026$29.40
Jaen Juan C.SellJul 9, 2026$30.05
Jaen Juan C.SellJun 24, 2026$29.66
Jaen Juan C.SellJun 23, 2026$27.69

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$117.0M$51.0M$33.0M
Operating Income--$330.0M-$386.0M
Net Income-$307.0M-$283.0M-$353.0M
Op. Margin--647.1%-1169.7%
Net Margin-262.4%-554.9%-1069.7%
Balance Sheet
Total Assets-$1.1B$1.1B
Equity-$485.0M$631.0M
ROE--58.4%-55.9%
Per Share
EPS$-4.15$-3.14$-3.29
Cash Flow
Operating CF--$170.0M-$482.0M
CapEx$24.0M$6.0M$2.0M

Source: XBRL data in Arcus Biosciences, Inc. (RCUS)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate RCUS share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
RCUS shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202630$1.98B
Q2 202631$2.42B
Q1 202629$1.54B
Q4 202529$1.63B
Q3 202530$887.4M
Q2 202530$528.1M
Q1 202529$426.3M
Q4 202423$727.3M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 231 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

RCUS filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 4, 2026Analysis-
10-QNov 4, 2026Analysis
8-KOct 23, 2026Analysis-
8-KOct 21, 2026Analysis-
8-KOct 20, 2026Analysis-
4Aug 24, 2026--
8-KAug 5, 2026Analysis-
10-QAug 5, 2026Analysis
4Jul 13, 2026--
4Jun 24, 2026--
4Jun 12, 2026--
4Jun 12, 2026--
4Jun 12, 2026--
4Jun 12, 2026--
4Jun 12, 2026--
8-KJun 12, 2026Analysis-
4Jun 12, 2026--
4Jun 12, 2026--
4Jun 12, 2026--
4Jun 1, 2026-
4May 12, 2026-
4May 12, 2026-
8-KMay 5, 2026Analysis-
10-QMay 5, 2026Analysis
8-KApr 20, 2026Analysis-

Related Health Care companies

All Health Care →

RCUS SEC filings: frequently asked questions

Which institutions hold RCUS stock?

As of September 30, 2026, the largest Arcus Biosciences, Inc. (RCUS) holders among the 13F filers tracked by SignalX were Gilead Sciences ($811.7 million), BlackRock ($434.6 million), State Street Corp ($143.9 million), Vanguard Portfolio Management LLC ($114.7 million), Vanguard Capital Management LLC ($101.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was RCUS's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Arcus Biosciences, Inc. (RCUS) reported revenue of $33.0 million (down 35.3% from FY2024) and a net loss of $353.0 million. Diluted EPS was -$3.29. The figures come from the XBRL data in the 10-K.

What are the main risks in RCUS's latest 10-K?

In the 10-K filed February 25, 2026, Arcus Biosciences, Inc. (RCUS) flagged: Regulatory risk from Gilead collaboration amendment causing revenue catch-up of $143M in 2025, impacting timing and recognition of license income. Macroeconomic exposure to collaboration funding variability, e.g., Taiho option revenue dropped from $15M in 2024 to $7M in 2025. (AI summary of the Risk Factors section.)

What did RCUS report in its latest 8-K?

Arcus Biosciences, Inc. (RCUS) filed an 8-K on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Arcus reported financial results for the nine months ended September 30, 2026.

What are the latest RCUS SEC filings?

Arcus Biosciences, Inc. (RCUS) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on August 24, 2026.

What is RCUS's SEC CIK number?

Arcus Biosciences, Inc. (RCUS)'s SEC Central Index Key (CIK) is 1724521. EDGAR lists every RCUS filing under that number.

Ask anything about RCUS

The research agent reads RCUS's filings, financials, insider trades and 13F holders, then answers with sources.